On Hyperliquid, stock-related contracts exceeded $10 million in 24-hour trading volume more often than altcoin contracts, with 23 stock contracts versus 13 altcoin contracts. However, native altcoins still held a slight edge in total volume, posting about $1.254 billion compared to $1.222 billion for stock-related contracts. The altcoin volume was concentrated in a few contracts like HYPE and ZEC, which together accounted for nearly half of the altcoin volume. Overall, altcoin trading volume has declined significantly since September, while stock-related contract volume has grown, indicating a shift in market interest towards stock-linked instruments on the platform.
The story about stock-linked contracts on Hyperliquid is presented here with Pluang's market data for context. As of Oct 26, 2026 18:21 WIB, among 50 major cryptocurrencies tradable on Pluang, 26 rose and 23 fell. EGLD traded at Rp57.333 with a 2.29% decline and full buy-side order activity, contrasting with ALGO which rose 2.01% to Rp1.879 but had 98% sell orders. FTM fell 2.05% to Rp11.382, with a typical hold time of 88 days, illustrating varied investor behavior across assets.
Corxel Pharmaceuticals US and Amanat Acquisition Corp have agreed to merge, creating a publicly traded biopharmaceutical company focused on oral obesity treatments. The deal will raise approximately $377 million, including $300 million from private i...
Eikon Therapeutics presented updated data on EIK1001, a TLR7/8 dual-agonist, combined with pembrolizumab and chemotherapy for stage 4 non-small cell lung cancer (NSCLC) at the 2026 ESMO Congress. The treatment showed a 72% objective response rate and...
Microsoft, Alphabet, and Amazon together represent about 15% of the S&P 500 index. All three tech giants are scheduled to report their quarterly earnings within a two-day span. These earnings reports are highly anticipated as they provide insight int...
Conow, in partnership with Tuya Smart, has introduced the Atlas 6000 AC in Germany, a 6 kWh AC-coupled plug-and-play home battery designed to upgrade existing rooftop solar systems. This battery features AI-driven energy management that optimizes hou...
BioNTech and DualityBio announced that their Phase-3 clinical trial DYNASTY-Breast02 met its primary endpoint, demonstrating a statistically significant but moderate improvement in progression-free survival for Trastuzumab Pamirtecan compared to chem...
